Visualizing hypothesis tests in survival analysis under anticipated delayed effects
- PMID: 38708672
- DOI: 10.1002/pst.2393
Visualizing hypothesis tests in survival analysis under anticipated delayed effects
Abstract
What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we anticipate non-proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log-rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log-rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log-rank tests can achieve high power compared to the standard log-rank test, some choices of weights may lead to type-I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre-specified time point -a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long-term survival. In this article, we introduce a graphical approach for direct comparison of weighted log-rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison.
Keywords: delayed effects; pseudo‐value; score; survival test; visualization.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Freidlin B, Korn EL. Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis? J Clin Oncol. 2019;37(35):3455.
-
- Freidlin B, Korn EL. Reply to H. Uno et al and B. Huang et al. J Clin Oncol. 2020;38(17):2003‐2004.
-
- Huang B, Wei L‐J, Ludmir EB. Estimating treatment effect as the primary analysis in a comparative study: moving beyond p value. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(17):2001‐2002.
-
- Uno H, Lu T. Is the log‐rank and hazard ratio test/estimation the best approach for primary analysis for all trials? J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(17):2000‐2001.
-
- Lin RS, Lin J, Roychoudhury S, et al. Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Stat Biopharm Res. 2020;12(2):187‐198.
MeSH terms
LinkOut - more resources
Full Text Sources
